THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center

Department of Pathology
1515 Holcombe Boulevard, Unit 0085
Houston, Texas 77030-4095
Tel: 713-792-3205 Fax: 713-794-4630

# Pathology Report
## X20-019508

**XXXXXXXX**
**XXXXXXXX**
DOB: X/XX/XXXX
Sex: Female

Collected: 5/5/2020
Received: 8/28/2020 11:54 AM

Case Type: Outside

Submitting Provider:
**Stephanie Anne Rosen, MD**

## Addended Report: OUTSIDE

### Materials Received

| Accession#, Stained, Block, Unstained | Collected | Received |
|---|---|---|
| A. XXX-XXXX, 0 SS, 1 BLOCK, 0 USS | 5/5/2020 | 8/28/2020 |

### Addendum 1

Addendum to report additional testing performed and interpreted at MDACC at request of treating physician:

PD-L1 (clone 22C3) by immunohistochemistry NOT EXPRESSED/NEGATIVE. The Combined Positive Score (CPS) is less than 1.

Addendum electronically signed by Adel K. El-Naggar, MD on 3/2/2021 at 10:51 AM

### Diagnosis

One outside paraffin block (XXXXX):

Parotid gland, left, parotidectomy (representative #5):

HIGH-GRADE CARCINOMA WITH MYOEPITHELIAL DIFFERENTIATION, See comment.
Size:at least 3 cm by report
Lymphovascular invasion, present, multifocal
Perineural invasion: not evaluable
Margins: EXTENDING TO INKED RESECTION MARGIN.

Electronically signed by Michelle Williams, MD on 9/7/2020 at 1:23 AM

### Comment

The tumor is high-grade thought fairly monomorphic with areas of necrosis. Immunohistochemical stains performed at MD Anderson Cancer Center show that the neoplastic cells are strongly immunoreactive to CK7, p40, Bcl-2 and SMA, while showing no expression for DOG-1. Per outside report (slides not received/reviewed), the neoplastic cells were negative for HER2, AR, SOX10, S100, mammoglobin, c-kit and GFAP. Ki-67 stain showed proliferation in 20% of neoplastic cells.

The features are compatible with a salivary primary. No definitive precursor lesion seen on representative sections though this could have arising as a carcinoma -ex pleomorphic adenoma or high-grade transformation from a pre-existing process. Clinical correlation is advised.

### Disclaimer

"Some tests reported here may have been developed and performance characteristics determined by UT MD Anderson Pathology and Laboratory Medicine. These tests have not been specifically cleared or approved by the U.S. Food and Drug Administration. If applicable, controls were reviewed and showed appropriate reactivity."

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center

Department of Pathology
1515 Holcombe Boulevard, Unit 0085
Houston, Texas 77030-4095
Tel: 713-792-3205 Fax: 713-794-4630

# Pathology Report
## X20-019508

**XXXXXXXX**
**XXXXXXXX**
DOB: X/XX/XXXX
Sex: Female

Collected: 5/5/2020
Received: 8/28/2020 11:54 AM

Case Type: Outside

Submitting Provider:
**Stephanie Anne Rosen, MD**